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CotE is a coat protein that is present in the spores of Clostridium difficile, an
obligate anaerobic bacterium and a pathogen that is a leading cause of
antibiotic-associated diarrhoea in hospital patients. Spores serve as the agents of
disease transmission, and CotE has been implicated in their attachment to the
gut epithelium and subsequent colonization of the host. CotE consists of an
N-terminal peroxiredoxin domain and a C-terminal chitinase domain. Here, a
C-terminal fragment of CotE comprising residues 349–712 has been crystallized
and its structure has been determined to reveal a core eight-stranded -barrel
fold with a neighbouring subdomain containing a five-stranded -sheet. A
prominent groove running across the top of the barrel is lined by residues that
are conserved in family 18 glycosyl hydrolases and which participate in catalysis.
Electron density identified in the groove defines the pentapeptide Gly-Pro-Ala-
Met-Lys derived from the N-terminus of the protein following proteolytic
cleavage to remove an affinity-purification tag. These observations suggest the
possibility of designing peptidomimetics to block C. difficile transmission.
1. Introduction
Clostridium difficile is an anaerobic, Gram-positive, spore-
forming bacterium and an animal pathogen which has
emerged as the most frequent cause of antibiotic-associated
hospital-acquired diarrhoea (Smits et al., 2016). It is estimated
that there are half a million new cases each year of infection
with C. difficile (CDI), augmented by 75 000–175 000 cases of
recurrent CDI. Treatment with antibiotics such as fidaxomicin
cures 90% of new cases of CDI; however, recurrent infection
is common and thousands of patients are on costly long-term
antibiotic treatment, with more than 25 000 deaths per annum
in the USA alone (Lessa et al., 2015). The disease follows
antibiotic therapy, which disrupts the normal gut microflora,
providing an opportunity for C. difficile colonization. The
pathogen causes a range of clinical conditions in humans
which range from mild diarrhoea to life-threatening pseudo-
membranous colitis, toxic megacolon and colonic perforation.
Spores play an important role in CDI as the agents of
disease transmission. As robust and metabolically dormant
structures, C. difficile spores can survive the dysbiosis of the
gut microflora induced by antibiotic treatment. The resulting
perturbation of the intestinal microbiota creates an environ-
ment in which the spore can germinate and proliferate as
ISSN 2053-230X
vegetatively growing cells, leading to colonization of the
gastrointestinal tract. Disease is primarily associated with the
secretion of two inflammatory cytotoxins, TcdA and TcdB,
which are responsible for tissue damage (Shen, 2012). These
large toxins enter the cells of the colonic epithelium, where
they glucosylate small GTPases, disrupting signalling in these
cells and giving rise to cytopathic effects and cytoxicity. Toxin
synthesis and spore formation by C. difficile may take place
simultaneously upon nutrient limitation, so that while non-
sporulating cells in the population produce toxins to generate
nutrients, the sporulating cells are designed for survival,
dissemination and the initiation of new infections (Daou et al.,
2019).
The spore has an elaborate multi-layered structure.
Analysis of the proteins released from spores of C. difficile
following treatment with SDS–borate–dithiothreitol identified
a number of spore-coat enzymes, including superoxide
dismutase and catalase (Permpoonpattana et al., 2011).
Among the most interesting of the discovered proteins was
CotE, an 81 kDa protein comprising an N-terminal domain
homologous to 1-Cys peroxiredoxins, a central cysteine-rich
interdomain region and a C-terminal domain with homology
to family 18 glycosyl hydrolases (GH18). The corresponding
enzyme activities were demonstrated for purified recombinant
polypeptides comprising these domains (Permpoonpattana et
al., 2013). The roles of these enzymatic activities in the spore
are intriguing. Insertional mutagenesis showed that cotE is not
essential for spore integrity (Permpoonpattana et al., 2013);
however, in animal models of CDI, when CotE is absent the
capacity of spores to colonize the intestine and induce viru-
lence is markedly reduced (Hong et al., 2017). It was proposed
that CotE facilitates host colonization by binding to the mucus
layer of the intestine. This in turn implies that CotE may be a
target for the prevention of or intervention in CDI. To build a
greater understanding of structure–function relationships and
to provide a platform for future inhibitor discovery, we have
determined crystal structures of the chitinase domain of CotE.
2. Materials and methods
2.1. Macromolecule production
2.1.1. Cloning. The oligonucleotide primers CotE-349F and
CotE-712R (Table 1) were used to amplify a 1119 bp fragment
from a pET-28b plasmid derivative harbouring a cotE
sequence codon-optimized for expression in Escherichia coli.
The fragment produced by polymerase chain reaction (PCR)
was inserted into the plasmid pETYSBLLIC3C (Fogg &
Wilkinson, 2008) by the In-Fusion method (Clontech
Laboratories) and the products were used to transform E. coli
strain XL1-Blue. Plasmids from kanamycin-resistant colonies
were prepared and their ‘cloned’ DNA inserts were sequenced
to confirm the presence and authenticity of the expected
inserts. The plasmid pETYSBLLIC3C-CotEC was used to
transform E. coli BL21 (DE3) cells. It encodes residues
349–712 of CotE fused N-terminally to the sequence
MGSSHHHHHHSSGLEVLFQGPA comprising a human
rhinovirus (HRV) 3C-cleavable hexahistidine tag (Table 1).
2.1.2. Protein purification. Recombinant protein was
produced in E. coli BL21(DE3) cells. The cells were grown
with shaking at 310 K in Luria–Bertani broth containing
30 mg ml1 kanamycin to an OD600 of 0.6–0.8. Recombinant
protein production was induced by the addition of 1 mM
isopropyl -d-1-thiogalactopyranoside and incubation at
289 K for 20 h. The cells were harvested by centrifugation, the
pellet was resuspended in buffer A (50 mM Tris–HCl pH 7.5,
500 mM NaCl, 10 mM imidazole), to which an EDTA-free
protease-inhibitor cocktail tablet (Roche Diagnostics, USA)
had been added, and the cells were lysed by sonication on ice.
The soluble cell extract was collected following centrifugation
and CotE(349–712) was purified in three steps, each of which
was carried out at room temperature. Firstly, the soluble cell
supernatant was loaded onto a 5 ml nickel-charged HisTrap
column (Amersham Pharmacia) equilibrated in buffer A.
After washing, the column was developed with a 10–500 mM
imidazole gradient in buffer A. Fractions containing
CotE(349–712) were identified and pooled. The pooled
sample (2.5 mg ml1 protein concentration) was treated
with a 1:50 ratio of HRV 3C protease (purified in-house) to
cleave off the N-terminal tag with simultaneous dialysis
overnight against buffer B (20 mM Tris–HCl pH 7.5, 150 mM
NaCl). The cleavage products were passed over a second Ni–
NTA agarose column equilibrated in buffer B. In this step,
highly purified untagged protein was identified in the flow-
through fractions, which were combined, concentrated by
centrifugal ultrafiltration (Amicon Ultra) and passed through
a Superdex S200 column in buffer B. After gel filtration, the
molecular mass of the purified protein was measured by
electrospray ionization mass spectrometry to be 17 339 Da,
which is within 1 Da of the calculated mass of CotE(349–712)
with an N-terminal Gly-Pro-Ala sequence representing a
vestige of the cloning and proteolysis procedure.
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Table 1
Macromolecule-production information.
Source organism C. difficile
DNA source Synthetic codon-optimized sequence
Forward primer CotE-349F 50-TCCAGGGACCAGCAATGAAAACCCTGA
AAGATAGC-30
Reverse primer CotE-712R 50-TGAGGAGAAGGCGCGTTAAAACTGGCC
ATAAATACCTTCC-30
Cloning vector pETYSBLLIC3C
Expression vector pETYSBLLIC3C
Expression host E. coli BL21(DE3)
Complete amino-acid sequence
of the construct produced
MGSSHHHHHHSSGLEVLFQGPAMKTLKDSK
KLVRPQITDPYNPIVENANCPDINPIVA
EYVLGNPTNVDAQLLDAVIFAFAEIDQS
GNLFIPYPRFLNQLLALKGEKPSLKVIV
AIGGWGAEGFSDAALTPTSRYNFARQVN
QMINEYALDGIDIDWEYPGSSASGITSR
PQDRENFTLLLTAIRDVIGDDKWLSVAG
TGDRGYINSSAEIDKIAPIIDYFNLMSY
DFTAGETGPNGRKHQANLFDSDLSLPGY
SVDAMVRNLENAGMPSEKILLGIPFYGR
LGATITRTYDELRRDYINKNGYEYRFDN
TAQVPYLVKDGDFAMSYDDALSIFLKTQ
YVLRNCLGGVFSWTSTYDQANILARTMS
IGINDPEVLKEELEGIYGQF
2.2. Crystallization
Protein concentrations were determined with an Epoch
Microplate Spectrophotometer using an extinction coefficient
at 280 nm calculated from the sequence. Crystallization
experiments were set up as sitting drops in 96-well plates using
Hydra 96 and Mosquito liquid-handling systems to dispense
the reservoir and drop solutions, respectively. Drops consisting
of 150 nl 20 mg ml1 protein solution in 20 mM Tris–HCl pH
8.0, 150 mM NaCl and 150 nl reservoir solution were equili-
brated against 0.1 ml reservoir solution. Crystals of CotE(349–
712) were obtained following screening experiments with
Clear Strategy Screens I and II (Brzozowski & Walton, 2001)
under conditions that contained PEG 3350. Refinement of
these conditions in a hanging-drop format led to the growth of
well diffracting crystals from drops that were formed by
mixing 1 ml protein solution with 2 ml reservoir solution
composed of 200 mM ammonium phosphate, 22.5% PEG 3350
and were equilibrated against 1 ml reservoir solution (Table 2).
These crystals belonged to space group P21 and are referred to
as the monoclinic crystal form.
Following the discovery of electron density in the putative
active-site region, we sought to remove the co-purifying
ligand. For this purpose, we immobilized the His6-tagged
CotE(349–712) on a Ni2+-chelation column in buffer A and
washed the column extensively with buffer A containing 2M
guanidine hydrochloride followed by a 2–0M descending
gradient of guanidine hydrochloride in buffer A. The poly-
histidine tag was subsequently removed from the protein as
described above. Crystallization experiments produced
diffracting crystals from hanging drops formed by mixing 2 ml
20 mg ml1 CotE(349–712) with 3 ml well solution consisting
of 1 ml 0.1M sodium malonate pH 5.5, 13% PEG 3350 and
3 ml pentaethylene glycol monooctyl ether (C8E5) (Table 2).
These crystals belonged to space group P6122 and are referred
to as the hexagonal crystal form.
2.3. Data collection and processing
Single crystals of CotE(349–712) were captured from crys-
tallization drops in fine nylon loops and transferred to a
solution of mother liquor containing 15%(v/v) glycerol prior
to cryocooling in liquid nitrogen. Crystals were tested on an
in-house system and the best diffracting crystals were chosen
and sent to Diamond Light Source (DLS) for data collection
to high resolution. For the monoclinic and hexagonal crystal
forms, data were collected on beamlines I02 and I03, respec-
tivley. The data were processed using the 3dii option in xia2
(Winter, 2010) and extended to 1.3 and 2.2 A˚ resolution,
respectively, for the monoclinic and hexagonal crystal forms
(Table 3). For both crystal forms, there is one protein molecule
per asymmetric unit.
2.4. Structure solution and refinement
The structures of CotE(349–712) were determined and
refined using the CCP4 suite of software as implemented in
the CCP4i2 graphical interface (Potterton et al., 2018). The
structure of the monoclinic crystal form was solved by mole-
cular replacement in Phaser (McCoy et al., 2007) using the
coordinate set for the catalytic domain of chitinase A1
(ChiA1) from Bacillus circulans (PDB entry 1itx; Matsumoto
et al., 1999) as the search model. The proteins share 35%
sequence identity across 353 and 468 aligned residues of CotE
and ChiA1, respectively. The resulting model was refined in
REFMAC5 (Murshudov et al., 2011) and automatic model
building was then performed using Buccaneer (Cowtan, 2006).
This was followed by iterative rounds of manual model
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Table 2
Crystallization.
Crystal CotE(349–712), monoclinic CotE(349–712), hexagonal
Method Vapour diffusion in hanging drops Vapour diffusion in hanging drops
Plate type 24-well 24-well
Temperature (K) 291 291
Protein concentration (mg ml1) 20 20
Buffer composition of protein solution 20 mM Tris–HCl pH 8.0, 150 mM NaCl 50 mM Tris–HCl pH 7.5, 500 mM NaCl, 10 mM imidazole
Composition of reservoir solution 200 mM ammonium phosphate, 22.5% PEG 3350 1 ml 0.1M sodium malonate pH 5.5, 13% PEG 3350 and 3 ml C8E5
Volume and ratio of drop 3 ml (1 ml protein solution + 2 ml reservoir solution) 5 ml (2 ml protein solution + 3 ml reservoir solution)
Volume of reservoir (ml) 1 1
Table 3
Data collection and processing.
Values in parentheses are for the outer shell.
Crystal
CotE(349–712),
monoclinic
CotE(349–712),
hexagonal
Diffraction source I02, DLS I03, DLS
Wavelength (A˚) 0.9795 0.9763
Temperature (K) 100 100
Detector Dectris PILATUS3
6M-F
Dectris PILATUS3
6M
Crystal-to-detector distance
(mm)
218.05 390.17
Rotation range per image () 0.1 0.1
Total rotation range () 250 180
Exposure time per image (s) 0.04 0.04
Space group P21 P6122
a, b, c (A˚) 45.9, 54.9, 80.3 82.1, 82.1, 325.9
, ,  () 90, 101.4, 90 90, 90, 120
Resolution range (A˚) 26.3–1.30 (1.32–1.30) 81.41–2.17 (2.23–2.17)
Total No. of reflections 434288 (21619) 654223 (47083)
No. of unique reflections 94345 (4564) 35657 (2551)
Completeness (%) 97.9 (96.1) 100 (100)
Multiplicity 4.6 (4.7) 18.3 (18.5)
hI/(I )i 18.0 (6.5) 9.5 (1.5)†
Rmeas 0.058 (0.31) 0.19 (2.43)
CC1/2 0.997 (0.954) 1.0 (0.64)
Overall B factor from
Wilson plot (A˚2)
9.3 39.1
† The mean I/(I) falls below 2 at a resolution of 2.2 A˚. The data yielded valuable
information as shown by CC1/2.
building in Coot (Emsley et al., 2010) and refinement in
REFMAC5. The refinement statistics are summarized in
Table 4. The structure of the hexagonal crystal form was
solved by molecular replacement using the refined coordinates
of the structure of the monoclinic form.
3. Results and discussion
3.1. Determination of the structure of the CotE chitinase
domain
We initiated structural studies of CotE by generating a
series of expression constructs encoding C-terminal fragments
of different lengths fused to a cleavable polyhistidine tag. This
allowed us to identify CotE(349–712) as a stable, soluble
fragment. The fragment encompasses the chitinase domain,
which is predicted to span residues 380–685. This protein was
purified from overproducing E. coli by immobilized nickel-
affinity chromatography, cleavage to remove the affinity tag
and gel-filtration chromatography. The protein was first crys-
tallized from polyethylene glycol 3350-containing solutions.
The crystals belonged to space group P21, with a single protein
molecule in the asymmetric unit and a solvent content of 48%.
Data extending to 1.3 A˚ resolution were collected at the
Diamond Light Source synchrotron-radiation source and the
structure was solved by molecular replacement using the
coordinates of the catalytic domain of chitinase A1 from
B. circulans (PDB entry 1itx; Matsumoto et al., 1999) as the
search model. The CotE(349–712) structure has been refined
to give a crystallographic R value of 10.6% (Rfree = 13.3%) for
a model comprising residues Ile363–Phe712, 490 waters and a
pentapeptide-like entity (currently modelled as Gly-Pro-Ala-
Met-Lys) defined by residual electron density located in the
active-site region of the structure.
3.2. Structure description
CotE(349–712) has a classical parallel eight-stranded -
barrel at its core, on top of which the substrate-binding site
resides (Fig. 1). The ()8-barrel is compact, with the excep-
tion of significant insertions following strands 6 and 7.
Following 7, residues 605–655 form a distinct subdomain
comprising a five-stranded -sheet and an -helix which packs
across one face of this sheet. The opposite face of the sheet
packs against the meandering segment of the polypeptide
following strand 6, which spans residues 550–580. Much of
the structure is covalently closed through a disulfide bond
linking residues Cys376 and Cys670 (Fig. 1).
A search of the Protein Data Bank for structures similar to
the CotE chitinase domain revealed a plethora of coordinate
sets with Q-scores greater than 0.5, corresponding to r.m.s.d.
values in the range 1.3–1.4 A˚ over 300 or so C atoms of
matched residues. These included human chitinase/chito-
triosidase (PDB entry 1lg2; Fusetti et al., 2002), the mouse
lectin YM1 (PDB entry 1vf8; Tsai et al., 2004) and bacterial
chitinases from Serratia proteamaculans (PDB entry 4lgx;
Madhuprakash et al., 2015) and Klebsiella pneumonia (PDB
entry 3qok; Midwest Center for Structural Genomics,
unpublished work) variously in complexes with mono-
saccharides, disaccharides and oligosaccharides as well as
oligosaccharide and peptide-based inhibitors.
3.3. The substrate-binding and active site
A pronounced groove runs across the top of the molecule
when viewed in the orientation shown in Fig. 1(c). In family
GH18 enzymes, this forms the substrate-binding and active
site. As seen in the structures of other GH18 family members,
this groove has a markedly negative electrostatic potential
(Figs. 1c and 1d). Located in this groove, we observed a strong
positive feature in the electron-density maps that we were able
to model as a pentapeptide: Gly-Pro-Ala-Met-Lys (Fig. 2a).
There is uncertainty for the side chain of residue 5, but the
sequence otherwise corresponds to the first five residues of the
expected product of HRV 3C protease cleavage of the
recombinant fusion protein. The Gly-Pro-Ala segment is a
vestige of the cleavage-recognition sequence, with the Met-
Lys segment constituting residues 349 and 350 of CotE. The
binding site for the peptide is circumscribed by residues
Met550, Tyr485, Glu484, Trp445, Asp553, Ala556, Arg608,
Thr614, Thr616, Tyr606, Tyr681 and Trp677, forming a
protein–peptide interface of 362 A˚2 (Fig. 2b).
The -amino group of the peptide makes an ion-pairing
interaction with the side-chain carboxylate of Glu484 and a
charge–dipole interaction with the phenolic hydroxyl group of
Tyr485, as well as polar interactions with surrounding water
molecules, one of which forms a bridging polar interaction
with the carboxylate of Asp553 (Fig. 2b). The face of the
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Table 4
Structure refinement.
Values in parentheses are for the outer shell.
Crystal
CotE(349–712),
monoclinic
CotE(349–712),
hexagonal
Resolution range (A˚) 45.09–1.30 (1.33–1.30) 54.37–2.10 (2.15–2.10)
Completeness (%) 97.89 (96.11) 99.96 (99.93)
 Cutoff None None
No. of reflections
Working set 89793 (6466) 37274 (2679)
Test set 4557 (328) 1918 (154)
Final Rcryst 0.106 (0.119) 0.22 (0.41)
Final Rfree 0.133 (0.158) 0.27 (0.43)
Cruickshank DPI 0.039
No. of non-H atoms
Protein 2843 2699
Additives 53 14
Ligand 33 —
Water 490 138
Total 3419 2851
R.m.s. deviations
Bonds (A˚) 0.020 0.016
Angles () 2.47 1.78
Average B factors (A˚2)
Protein 13.5 58.8
Additives 33.0 90.3
Ligand 28.2 —
Water 29.6 64.0
Ramachandran plot
Favoured regions (%) 90.1 87.5
Additionally allowed (%) 9.9 11.8
Outliers (%) 0 0.3
pyrrolidine ring of Pro2 and the residue 1–2 peptide bond
pack closely with the face of the indole ring of Trp445. The
carbonyl O atom of Pro2 makes an intramolecular hydrogen
bond to the amide >N–H of Lys5, while the amide >N–H of
Ala3 makes a charge–dipole interaction with the side-chain
carboxylate of Asp553 (Fig. 2b). Further along the ligand
backbone, the carbonyl O atom of Ala3 forms another charge–
dipole interaction with the guanidino group of Arg608. The
backbone >N—H of Met4 forms a hydrogen bond to a well
ordered water molecule, with bridging hydrogen bonds to the
indole N atom of Trp677 and the phenolic hydroxy group of
Tyr681. The side chain of Met4 projects into a pocket lined by
the side chains of the protein residues Tyr606 and Tyr681 and
the aliphatic faces of Thr614 and Thr616 (Fig. 2b). The elec-
tron density becomes more diffuse at Lys5, precluding further
model building.
The peptide residing in the binding groove may be an
N-terminal degradation product of proteolysis. This would
imply high-affinity binding, since the peptide is evidently
retained on passage through a gel-filtration column. Alter-
natively, this pentapeptide may represent the amino-terminus
of the intact CotE chitinase-domain polypeptide. If this is the
case, then the intervening residues Thr351–Thr362, which are
not visible in the electron-density maps, are missing owing to
disorder. Lys5 of the peptide and Ile363, the first residue of the
polypeptide defined by the electron-density maps, are on
opposite faces of the chitinase domain (Fig. 1a) and 45 A˚
apart, so it is unlikely that they belong to the same molecule.
The same lysine and Ile363 in the protein molecule generated
by the symmetry operation (x, y  1/2, z) are separated by
24 A˚, a distance that could be spanned by the 12 ‘missing’
residues.
3.4. Mechanistic considerations
Chitinases are enzymes that catalyse glycosidic bond
cleavage in -1,4-linked N-acetylglucosamine (GlcNAc)-
containing polymers such as chitin. Chitin is widely distributed
in nature, but the physiological substrate of CotE is not
known. Polymeric structures containing GlcNAc are present
in the cell wall of C. difficile, a structure that is known to
undergo remodelling during spore formation. The integrity of
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Figure 1
The overall structure of the chitinase domain of CotE. (a, b) Ribbon rendering of the polypeptide chain colour-ramped from the N-terminus (Ile363,
blue) to the C-terminus (Phe712, red). The atoms of the disulfide bond linking cysteines 376 and 670 are shown as spheres, as are the atoms of the
pentapetide ligand located in the active site. These atoms are coloured by element, with C in grey, O in red, N in blue and S in yellow. The views are from
the side of the -barrel (a) and looking down into it (b). (c, d) Electrostatic surface renderings of the protein in similar orientations to those in (a) and
(b), respectively. The prominent groove that forms the active site and its markedly negative electrostatic potential are apparent.
C. difficile spores, however, is unaffected by deletion of cotE,
suggesting that the substrate may be host-derived. Chitin does
not occur in mammals, suggesting that the target of CotE
action during infection is a glycoprotein, and evidence has
been presented to show that CotE facilitates spore binding to
mucin and mucin degradation (Hong et al., 2017).
The family 18 glycosyl hydrolases carry a conserved acidic
motif, which occurs in CotE as D477GIDIDWEY485. As shown
in Fig. 2(b), Glu484 and Tyr485 form polar contacts to the
-amino group of the bound peptide in CotE. The reaction
mechanisms of these enzymes feature neighbouring-group
assistance, in which the carbonyl of the acetyl group on the
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Figure 2
Peptide–CotE interactions. Stereo images are shown with the pentapeptide ligand in ball-and-stick format. (a) The peptide with its associated electron
density in maps calculated with coefficients 2mFo  DFc and contoured at 1. Residues are labelled using the single-letter code. (b) The pentapeptide
ligand displayed as above, with surrounding protein residues in cylinder format (with three-letter code labels). Atoms are coloured by element type (O,
red; N, blue; S, yellow; C in green for the ligand or light grey for the protein). Neighbouring water molecules are shown as red spheres. Polar interactions
are denoted by dashed lines. (c) Superposition of the methylallosamidin ligand (blue C atoms) from the complex with human chitinase (PDB entry 1hkj;
Rao et al., 2003) and the GPAMK ligand (green C atoms) from CotE. Selected conserved residues are shown and numbered as in CotE. The structures
were displayed in CCP4mg (McNicholas et al., 2011) following SSM superposition, which gave a r.m.s.d. of 1.4 A˚ for 292 matching atoms. (d) The argadin
(white; PDB entry 1waw; Rao et al., 2005), methylallosamidin (blue; PDB entry 1hkj; Rao et al., 2003) and chitobiose (coloured by atoms with C in grey
and O in red; PDB entry 4wkh; Fadel et al., 2015) ligands from human chitinase structures superposed on the GPAMK ligand from CotE. The binding
subsites 3, 2 and 1 are labelled.
GlcNAc in the 1 site acts as the nucleophile (Terwisscha van
Scheltinga et al., 1995; Tews et al., 1997). An Asp residue
(corresponding to Asp482 in CotE) stabilizes the developing
positive charge on the –NH of the acetyl group, while a
glutamic acid (corresponding to Glu484) promotes breakage
of the -1,4 glycosidic linkage between residues bound in the
1 and +1 subsites by protonating the leaving group. This
results in the formation of an oxazolinium intermediate in the
1 site, the positive charge of which is stabilized by neigh-
bouring carboxylates. A water molecule, activated by the Glu
residue now serving as a base, attacks at the anomeric C atom
with opening of the oxazolinium ring and reformation of the
N-acetyl group. As a result, there is an overall retention of
configuration at the anomeric C atom (Terwisscha van
Scheltinga et al., 1995).
There has been much research into chitinase inhibition,
since chitinase inhibitors have potential applications in the
treatment of human diseases, including those resulting from
bacterial infections (Frederiksen et al., 2013). As a result,
many classes of chitinase inhibitor have been discovered,
including sugar derivatives such as the natural product allo-
samidin and derivatives thereof (Sakuda et al., 1986; Mac-
donald et al., 2010). The structure of the CotE–peptide
complex is compared with that of human macrophage chit-
inase bound to methylallosamidin (Rao et al., 2003) in Fig. 2(c).
Following structure superposition by the SSM procedure as
implemented in CCP4mg (McNicholas et al., 2011), the r.m.s.d.
for 292 matching atoms is 1.4 A˚. Methylallosamidin, which
consists of two -1,4-linked N-acetylglucosamine residues
attached to allosamizoline, binds in the 3 to 1 subsites in
the chitinase substrate-binding site. Allosamizoline is bicyclic,
consisting of a cyclopentitol ring fused to an oxazoline, which
mimics the oxazolinium intermediate in the chitinase-
catalysed reaction. As seen in Fig. 2(c), the peptide-binding
site in CotE partially overlaps with the allosamidin-binding
site in human chitinase, particularly in the 3 and2 subsites.
The cyclic pentapeptides argifin and argadin are of interest
in relation to the peptide bound in the substrate-binding site
of the chitinase domain of CotE. Argifin and argadin are
produced by fungi and have a high potency (nanomolar)
towards their insect chitinase targets (Shiomi et al., 2000).
Structures have been determined of these inhibitors in
complex with bacterial and human chitinases, revealing
mimicry of the natural carbohydrate substrate (Rao et al.,
2005). Relative to the GPAMK peptide bound to CotE, the
cyclic peptide argadin binds more deeply in the substrate-
binding cleft. In Fig. 2(d), the argadin (white), methylallo-
samidin (blue) and chitobiose (grey) ligands from human
chitinase complexes are overlaid on the GPAMK peptide
(green) from the CotE complex. Argadin occupies subsites2
and 1, defined by the binding of the chitobiose (GlcNAc2),
and extends towards the +1 site to make interactions with the
research communications
Acta Cryst. (2020). F76, 241–249 Whittingham et al.  GH18 domain of CotE 247
Figure 3
Domain swapping in the chitinase domain of CotE. (a) Ribbon rendering of the chitinase domain in the P6122 crystal structure. The chain is colour-
ramped as in Fig. 1(a), and the C atoms and side chains of cysteines 376 and 670 are shown as spheres. The C-terminal residues 627–712 extend away
from the -barrel so as to pack onto and complete the -barrel of a crystallographic symmmetry mate, as shown in (c), where the two subunits of the
domain-swapped dimer are coloured light blue and green, respectively. The eighth strand of each -barrel is provided by the partner subunit. (b) A
juxtaposition of the C-terminal swapped domains (residues 627–712) in the P21 and P6122 crystal forms, coloured light green and ice blue, respectively,
relative to the -barrel domain (in white) following the superposition of residues 358–623 is shown.
catalytic residues (Fadel et al., 2015). In its complex, the
argadin conformation is stabilized by extensive intramolecular
polar interactions. In contrast, there are few polar interactions
with the protein; instead, there is quite an extensive buried
surface area which will contribute to higher affinity.
3.5. Domain swapping
Before we confirmed the identity of the peptide ligand in
the chitinase-domain substrate-binding groove, we sought to
remove this ‘ligand’ and crystallize the protein in an un-
liganded form. To obtain unliganded CotE(349–712), the first
Ni–NTA column-chromatography purification procedure was
modified so that after the binding and washing steps, the
column was washed with buffer C (buffer A containing 2M
guanidine hydrochloride) to partially unfold the immobilized
protein and allow the dissociation of endogenous ligand(s).
We have used this technique previously to remove ligands
from peptide-binding proteins (Hughes et al., 2019). After
washing with ten column volumes of buffer C, the concen-
tration of guanidine hydrochloride was decreased to zero in a
series of five steps. The protein was then eluted from the
column by applying an increasing imidazole concentration
gradient. The eluted recombinant protein was subsequently
cleaved with HRV 3C protease and further purified as before.
In retrospect this strategy was flawed, since the peptide
ligand GPAMK is presumably generated during or after the
HRV 3C protease-cleavage step. The partially unfolded/
refolded protein was crystallized in a different crystal form
(P6122). Solution of the structure and refinement against data
extending to 2.1 A˚ resolution revealed that the substrate-
binding groove was indeed empty. However, the structure
proved to be of a 3D domain-swapped dimer. In this structure
(Fig. 3), domain exchange takes place at residue Lys627. As is
usual following 3D domain swapping, the respective domains
in the two structures can be closely superposed. Thus, 244 C
atoms in the residue range 368–623 can be superposed with an
r.m.s.d. of 0.44 A˚, while similarly 78 C atoms of residues 627–
708 can be superposed with an r.m.s.d. of 0.43 A˚.
3D domain swapping is commonly observed in protein
crystal structures since it is promoted by high protein
concentrations and/or partially denaturing conditions (Schlu-
negger et al., 1997). Indeed, we have observed this phenom-
enon in crystals of other sporulation proteins. In Spo0A from
B. subtilis (Lewis et al., 2000) and CodY from C. difficile (Daou
et al., 2019) -helices are swapped, leading to dimeric and
hexameric assemblies, respectively, while in SpoIIE from
B. subtilis (Levdikov et al., 2012) three -strands from a
-sandwich are exchanged in a 3D domain-swapped dimer. In
almost all instances 3D domain swapping is a crystallographic
artefact and there is no evidence that the 3D domain-swapped
dimer of CotE(349–712) is physiologically significant. It is
nevertheless structurally interesting since it involves (i) the
exchange of a strand, 8, from the -barrel and (ii) the
breakage of the intramolecular disulfide bond between Cys376
and Cys670 and the formation of an intermolecular equiva-
lent.
3D domain swapping in the TIM barrel of a subunit of
tryptophan synthase (TrpA) from Streptococcus pneumoniae
was recently observed (Michalska et al., 2020). In TrpA, the
N-terminal strands 1 and 2 of the TIM barrel are exchanged in
dimer formation. In this paper, the authors surveyed 2000 or
so TIM-barrel structures in the PDB and found that the
integrity of the core barrel was always preserved. They
concluded that their TrpA structure is the first example of 3D
domain swapping that intrudes into the core of the barrel
(Michalska et al., 2020). The 3D domain-swapped CotE(349–
712) structure reported here is therefore the second example,
with the distinction that it is the C-terminal strand 8 of the
barrel that is swapped.
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